Literature DB >> 6967943

Two types of Ia-positive T cells. Synthesis and exchange of Ia antigens.

D T Yu, J M McCune, S M Fu, R J Winchester, H G Kunkel.   

Abstract

Two distinct types of Ia-positive T cells have been described. One type represents a blastoid T cell responding from stimulation by mitogens, antigens, and in allogeneic and autologous mixed lymphocyte culture reactions. This is a large cell that is strongly positive for Ia antigens as measured by a variety of different antisera. The other general type is a smaller cell with a lower expression of Ia antigens that is found at low levels in normal peripheral blood and is markedly elevated in various pathological states. It also rises rapidly after inoculation with tetanus toxoid and PPD in sensitized individuals. This cell does not incorporate thymidine and is enriched in the Tgamma fraction; it can be markedly concentrated from normal lymphocytes, and current evidence indicates that it is a T cell. The marked elevation of this cell in the blood of patients with rheumatoid arthritis is of special interest. Considerable evidence indicates that, at least in certain instances, the Ia antigens are synthetized by the cells that carry them. Incorporation of labeled amino acid experiments and the in vitro translation results presented above indicate this. However, the ready exchange of Ia antigens between cells in the experiments described indicates that uptake from other cells may be a significant source.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967943

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

Review 1.  T cell-mediated antigen presentation: a potential mechanism of infectious tolerance.

Authors:  M D Mannie
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Antigen-independent acquisition of MHC class II molecules by human T lymphocytes.

Authors:  Anita H Undale; Peter J van den Elsen; Esteban Celis
Journal:  Int Immunol       Date:  2004-09-06       Impact factor: 4.823

3.  The role of MHC class II antigenic determinants in the function of human antigen binding T8+ cells, monocytes and helper and suppressor factors.

Authors:  T Lehner; T Jones
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

4.  The alpha chain, not the beta chain of HLA-DR antigens participates in activation of T cells in autologous mixed lymphocyte reaction.

Authors:  R Palacios; L Claesson; G Möller; P A Peterson; E Möller
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

5.  Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity.

Authors:  A Moretta; G Pantaleo; L Moretta; J C Cerottini; M C Mingari
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

6.  Interaction of lactoferrin, monocytes, and T lymphocyte subsets in the regulation of steady-state granulopoiesis in vitro.

Authors:  G C Bagby; V D Rigas; R M Bennett; A A Vandenbark; H S Garewal
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

7.  Regulation of the human allogeneic proliferative response in vitro.

Authors:  E Carosella; A Bensussan; V Lepage; M Sasportes
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

8.  Immunohistological study of mononuclear cell infiltrate in malignant gliomas.

Authors:  M L Rossi; J T Hughes; M M Esiri; H B Coakham; D B Brownell
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

9.  Presence of HLA-D/DR antigens on the membrane of breast tumour cells.

Authors:  D Bernard; J C Maurizis; F Rusé; J Chassagne; P Chollet; B Sauvezie; M de Latour; R Plagne
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

10.  Alloantigens expressed on activated human T cells different from HLA-A, B, C, and DR antigens.

Authors:  M Gerbase de Lima; E E Wollman; V Lepage; L Degos; J Dausset
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.